The Vantage Team

As operators, investors and government officials, with 60+ years of experience, $2bn AUM and 200+ portfolio companies, we had to find another way to level the playing field for our key assets and partners maximizing their opportunity to bring novel innovations to market.

60+
Experience
Years combined
$2bn
AUM
Assets under management
200+
Portfolio
Companies
240+
Studies
Clinical trials in KZ

Our Commitment to Excellence

Expertise

World-class professionals with deep expertise in clinical research

Global Perspective

International experience across multiple markets and regulatory environments

Collaboration

Working closely with clients to achieve their drug development goals

Leadership Team

Our leadership team brings together decades of experience in clinical research, regulatory affairs, and healthcare innovation to drive excellence in everything we do.

DAK

Photo Coming Soon

Dr. Aida Kenzhebekova

Chief Executive Officer

Leading clinical research expert with 15+ years of experience in international pharmaceutical development. Dr. Kenzhebekova has successfully led over 200 clinical trials and has been instrumental in bringing numerous life-saving treatments to market.

Education:MD, PhD in Clinical Research
Experience:15+ years

Key Achievements

  • Led 200+ clinical trials
  • Published 50+ research papers
  • International recognition for excellence

Specialties

Clinical ResearchRegulatory AffairsStrategic Leadership
DMT

Photo Coming Soon

Dr. Murat Tulegenov

Chief Medical Officer

Renowned cardiologist and clinical investigator with extensive experience in cardiovascular trials. Dr. Tulegenov has been at the forefront of innovative cardiac treatments and has contributed significantly to advancing cardiovascular medicine.

Education:MD, PhD in Cardiology
Experience:12+ years

Key Achievements

  • Pioneered new cardiac procedures
  • International speaker and educator
  • Award-winning researcher

Specialties

CardiologyClinical TrialsMedical Affairs

Our Expert Team

Our diverse team of professionals brings together decades of experience in clinical research, regulatory affairs, and healthcare innovation.

Advisory Board

Our advisory board consists of world-renowned experts in regulatory affairs, biostatistics, and clinical research who guide our strategic direction and ensure the highest standards of excellence.

150+
Publications
25+
Countries
50+
Drug Approvals
28+
Years Combined
DSJ

Photo Coming Soon

Dr. Sarah Johnson

Head of Regulatory Affairs

Former FDA Senior Reviewer

International regulatory expert specializing in FDA and EMA submissions for pharmaceutical products. Dr. Johnson brings over 10 years of regulatory experience from the FDA.

Education:PhD in Regulatory Science
Experience:10+ years

Areas of Expertise

FDA SubmissionsEMA ComplianceRegulatory Strategy

Key Achievements

  • Former FDA Senior Reviewer
  • Led 50+ successful drug approvals
  • International regulatory consultant
PMC

Photo Coming Soon

Prof. Michael Chen

Chief Scientific Officer

Harvard Medical School

Distinguished researcher and biostatistician with expertise in clinical trial design and data analysis. Prof. Chen has published over 100 peer-reviewed papers.

Education:PhD in Biostatistics
Experience:18+ years

Areas of Expertise

BiostatisticsTrial DesignData Analysis

Key Achievements

  • 100+ peer-reviewed publications
  • International research collaborations
  • Award-winning statistician

Why Our Advisory Board Matters

Global Perspective

International expertise from leading institutions worldwide

Proven Track Record

Decades of successful clinical research and regulatory experience

Continuous Learning

Stay ahead with cutting-edge research and industry best practices